Open access
Open access
Powered by Google Translator Translator

Coronary Insufficiency

2023 AHA/ACC Guideline for chronic coronary disease – B-blockers downgraded in patients without recent MI or low ejection fraction

21 Jul, 2023 | 13:52h | UTC

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines – Journal of the American College of Cardiology

Key Perspectives: 2023 Multisociety Guideline for Managing Chronic Coronary Disease – American College of Cardiology

Top things to know: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease – American Heart Association

News Releases:

Symptom relief and healthy habits are top goals for treating chronic heart disease – American Heart Association

New ACC, AHA, Multi-Society Guideline Addresses Management of Chronic Coronary Disease – American College of Cardiology

Commentary: New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization – TCTMD

 

Commentary on Twitter with key points (thread – click for more)

 


M-A | P2Y12 inhibitors show superior efficacy over aspirin for secondary prevention in CAD

11 Jul, 2023 | 14:06h | UTC

P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Related:

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis – The Lancet (link to abstract – $ for full-text)

RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

 

Commentary on Twitter

 


M-A | Coronary revascularization in HF and CAD: a small but significant effect on mortality

2 Jun, 2023 | 12:31h | UTC

Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials – European Journal of Heart Failure

 


Consensus Paper | Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease

10 May, 2023 | 15:51h | UTC

Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease: 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Association for Acute CardioVascular Care (ACVC) and European Association of Preventive Cardiology (EAPC) – European Heart Journal – Cardiovascular Pharmacotherapy

 


Review | The bidirectional association between atrial fibrillation and myocardial infarction

8 May, 2023 | 12:54h | UTC

The bidirectional association between atrial fibrillation and myocardial infarction – Nature Reviews Cardiology (if the link is paywalled, try this one)

 

Commentary on Twitter

 


Cohort Study | Subclinical coronary atherosclerosis and risk for myocardial infarction

31 Mar, 2023 | 13:36h | UTC

Subclinical Coronary Atherosclerosis and Risk for Myocardial Infarction in a Danish Cohort: A Prospective Observational Cohort Study – Annals of Internal Medicine (link to abstract – $ for full-text)

Commentary: CTA-detected coronary artery disease associated with increased risk for myocardial infarction – ACP Internist

Related:

M-A: Evaluation of the incremental value of a coronary artery calcium score beyond traditional cardiovascular risk assessment.

New study challenges the idea that a coronary artery calcium score of 0 is enough for ruling out coronary stenosis in symptomatic patients, especially in young adults.

Cohort Study: Coronary Artery Calcium and Long-Term Risk of Death, Myocardial Infarction, and Stroke

USPSTF Statement: Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors

Research: Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome

The 10-Year Prognostic Value of Zero and Minimal CAC

 


Guideline | Diagnosis and treatment of vasospastic angina and coronary microvascular dysfunction

23 Mar, 2023 | 12:53h | UTC

JCS/CVIT/JCC 2023 Guideline Focused Update on Diagnosis and Treatment of Vasospastic Angina (Coronary Spastic Angina) and Coronary Microvascular Dysfunction – Circulation Journal (see PDF)

 


SR | Myocardial revascularization in patients with ischemic cardiomyopathy: for whom and how

14 Mar, 2023 | 13:46h | UTC

Myocardial Revascularization in Patients With Ischemic Cardiomyopathy: For Whom and How – Journal of the American Heart Association

 


M-A | Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk

8 Feb, 2023 | 12:16h | UTC

Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials – European Heart Journal (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts

8 Feb, 2023 | 12:14h | UTC

Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts – The Lancet (link to abstract – $ for full-text)

News Release: Digital marker for coronary artery disease built by researchers at Mount Sinai

Commentary: Machine learning used to generate a new holistic model for coronary artery disease – News Medical

 

Commentary from the author on Twitter (thread – click for more)

 


Transfusion thresholds for acute coronary syndromes — insights from the TRICS‐III trial and meta‐analysis

3 Feb, 2023 | 13:58h | UTC

Transfusion Thresholds for Acute Coronary Syndromes—Insights From the TRICS‐III Randomized Controlled Trial, Systematic Review, and Meta‐Analysis – Journal of the American Heart Association

 


Risk and trajectory of premature ischemic CVD in women with a history of pre-eclampsia: a nationwide register-based study

30 Jan, 2023 | 01:08h | UTC

Risk and trajectory of premature ischaemic cardiovascular disease in women with a history of pre-eclampsia: a nationwide register-based study – European Journal of Preventive Cardiology (free for a limited period)

News Release: Pre-eclampsia linked with four-fold higher risk of heart attack in decade after delivery – European Society of Cardiology

Commentaries:

Preeclampsia Increases Heart Attack, Stroke Risk for Up to 20 Years After Pregnancy – HCP Live

Preeclampsia in Pregnancy a Bad Sign for Women’s Future Heart Health – HealthDay

Related:

Cohort Study | Pre-eclampsia is associated with increased risk of premature-onset obstructive coronary artery stenosis.

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine

Pregnancy Complications and Risk of Cardiovascular Disease Later in Life: A Nationwide Cohort Study – Journal of the American Heart Association

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Gestational Hypertension and Future Risk of Cardiovascular Disease

Research: Conjoint Associations of Gestational Diabetes and Hypertension With Diabetes, Hypertension, and Cardiovascular Disease in Parents

 


2023 Guidelines on the diagnosis and management of chronic coronary syndrome

25 Jan, 2023 | 11:25h | UTC

2023 Guidelines of the Taiwan Society of Cardiology on the Diagnosis and Management of Chronic Coronary Syndrome – Acta Cardiologica Sinica

Related: 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology

 


Retrospective Study | Serial troponin-T and long-term outcomes in suspected acute coronary syndrome

24 Jan, 2023 | 14:09h | UTC

Serial troponin-T and long-term outcomes in suspected acute coronary syndrome – European Heart Journal

 

Commentary on Twitter

 


Review | Wellens syndrome: an important consideration in patients with chest pain

23 Jan, 2023 | 13:26h | UTC

Wellens syndrome: An important consideration in patients with chest pain – JAAPA

Commentary: Wellens Syndrome Important to Consider if Chest Pain: Key Points – American College of Cardiology

 


SR | Comparison of various calcium antagonists on vasospastic angina

18 Jan, 2023 | 14:16h | UTC

Comparison of various calcium antagonist on vasospastic angina: a systematic review – openheart

 


The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischemic heart disease

9 Jan, 2023 | 14:28h | UTC

The year in cardiovascular medicine 2022: the top 10 papers in acute cardiac care and ischaemic heart disease – European Heart Journal

 

Commentary on Twitter

 


AHA Scientific Statement | Management of acute coronary syndrome in the older adult population.

13 Dec, 2022 | 14:35h | UTC

Management of Acute Coronary Syndrome in the Older Adult Population: A Scientific Statement From the American Heart Association – Circulation

News Release: Hearts and bodies change with age, heart disease treatments may need to change, too – American Heart Association

Top Things to Know: Management of ACS in the Older Adult Population – American Heart Association

Commentaries: 

The Management of ACS in Older Patients: Is Age Just a Number? – American Heart Association

Cardiovascular Aging and Acute Coronary Syndromes: Unique Challenges and Solutions for Our Elderly Patients – American Heart Association

 


RCT | Utility of coronary CT angiography for patients with suspected acute coronary syndrome.

9 Dec, 2022 | 13:22h | UTC

Prospective RandOmised Trial of Emergency Cardiac Computerised Tomography (PROTECCT) – Heart

 

Commentary on Twitter

 

Under a http://creativecommons.org/licenses/by-nc/4.0/ License

 


Cohort Study | Race-dependent association of HDL-C levels with incident coronary artery disease.

23 Nov, 2022 | 14:02h | UTC

Race-Dependent Association of High-Density Lipoprotein Cholesterol Levels With Incident Coronary Artery Disease – Journal of the American College of Cardiology

Editorial: HDL-C in Black Adults for ASCVD Risk Calculation: Benefit or Barrier to Achieving Health Equity? – Journal of the American College of Cardiology

News Release: Study challenges “good” cholesterol’s role in universally predicting heart disease risk – National Institutes of Health

Commentary: Study suggests that HDL or ‘good’ cholesterol is less beneficial than previously thought, especially for Black adults – CNN

 


RCT | Clopidogrel is better than Aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

17 Nov, 2022 | 12:30h | UTC

Aspirin vs. Clopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOST-EXAM Extended Study – Circulation

Related: 

Meta-analysis of randomized trials: Clopidogrel is better than aspirin for the secondary prevention of cardiovascular events.

#ACC21 – RCT: Clopidogrel better than aspirin for chronic maintenance monotherapy after percutaneous coronary intervention.

 

Commentary on Twitter

https://twitter.com/CircAHA/status/1589647384073703426 

 


RCT | Bivalirudin is superior to heparin in patients with ST-segment elevation myocardial infarction undergoing primary PCI.

15 Nov, 2022 | 13:00h | UTC

Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial – The Lancet

Commentaries:

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI – TCTMD

Bivalirudin found to be safer and more effective than heparin for treating heart attack patients undergoing percutaneous coronary intervention – Mount Sinai School of Medicine

BivaliRudin with prolonged full-dose Infusion during primary PCI versus Heparin Trial – BRIGHT-4 – American College of Cardiology

 


RCT | Indobufen vs. aspirin on top of clopidogrel after coronary drug-eluting stent implantation.

11 Nov, 2022 | 14:03h | UTC

Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-eluting Stent Implantation (OPTION): a Randomized, Open-label, Endpoint-blinded, Non-inferiority Trial – Circulation

 

Commentary on Twitter

 


On the natural history of coronary artery disease: a longitudinal nationwide serial angiography study.

10 Nov, 2022 | 14:03h | UTC

On the Natural History of Coronary Artery Disease: A Longitudinal Nationwide Serial Angiography Study – Journal of the American Heart Association

 


Study Commentary | Radial artery beats both right internal thoracic artery and vein grafting at 15 years.

9 Nov, 2022 | 12:28h | UTC

(Not published yet, presented at the American Heart Association Scientific Sessions, November 6, 2022)

RAPCO: Radial Artery Beats Both RITA and Vein Grafting at 15 Years – TCTMD

See also:

Radial Artery Patency and Clinical Outcomes Study–Right Internal Thoracic Artery – RAPCO-RITA – American College of Cardiology

Radial Artery Patency and Clinical Outcomes Study–Saphenous Vein – RAPCO-SV – American College of Cardiology

Related:

Meta-analysis: Radial artery graft vs. saphenous vein graft in long-term cardiovascular outcomes among patients undergoing coronary artery bypass grafting

Meta-Analysis: Radial-Artery vs Saphenous-Vein Grafts in CABG

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.